SCHEMBL6287737

SCHEMBL6287737

CC(C)c1cnc(NC(=O)Nc2ccc(Cl)cc2)s1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 7/20 0.76
CCNE1 P24864 6/20 0.76
CDK5 Q00535 6/20 0.76
SMN1; SMN2 Q16637 6/20 0.69
RAB9A P51151 6/20 0.69
MEN1 O00255 3/20 0.69
KMT2A Q03164 3/20 0.69
MAPT P10636 2/20 0.69
NFKB1 P19838 1/20 0.69
NFKB2 Q00653 1/20 0.69
RELA Q04206 1/20 0.69
CNR1 P21554 1/20 0.63
POLB P06746 4/20 0.56
HTT P42858 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2D6 P10635 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
CASP3 P42574 1/20 0.53
SENP8 Q96LD8 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6284915 0.90 CDK2 (0.78) CDK2CCNE1CDK5SMN1; SMN2RAB9A
SCHEMBL6285271 0.88 CDK2 (0.78) CDK2CCNE1CDK5SMN1; SMN2RAB9A
SCHEMBL6282655 0.88 CDK2 (0.78) CDK2CCNE1CDK5SMN1; SMN2RAB9A
SCHEMBL6285973 0.86 CDK2 (0.67) CDK2CCNE1CDK5SMN1; SMN2RAB9A
SCHEMBL6287741 0.86 CDK2 (0.76) CDK2CCNE1CDK5SMN1; SMN2RAB9A
SCHEMBL6281782 0.86 CDK2 (0.76) CDK2CCNE1CDK5SMN1; SMN2RAB9A
SCHEMBL6284074 0.86 CDK2 (1.00) CDK2CCNE1CDK5SMN1; SMN2RAB9A
SCHEMBL6285642 0.85 CDK2 (0.74) CDK2CCNE1CDK5SMN1; SMN2RAB9A
SCHEMBL6283519 0.85 CDK2 (0.78) CDK2CCNE1CDK5SMN1; SMN2RAB9A
SCHEMBL6288000 0.85 CCNE1 (0.73) CDK2CCNE1CDK5SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US claimed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US claimed
US-6863647-B2 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN S.P.A. (IT) 2005-03-08 US disclosed
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US disclosed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 CDK2 3/4885CCNE1 83/4885CDK5 129/4885
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 CDK2 3/4885CCNE1 83/4885CDK5 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.